Posted by Michael Wonder on 19 Dec 2017
60° Pharmaceuticals submits new drug application to US FDA for anti-malarial drug tafenoquine
18 December 2017 - 60P will continue global regulatory strategy and pursue additional dossier submissions.
60 Degrees Pharmaceuticals (60P) announced it has submitted a new drug application to the United States FDA for the use of tafenoquine to prevent malaria in adults traveling to areas where malaria is prevalent.
60P entered into a cooperative research and development agreement with the U.S. Army Medical Materiel Development Activity (USAMMDA) in 2014 to develop Tafenoquine as a weekly prophylactic drug for the prevention of malaria. As malaria is the top infectious disease threat to U.S. Military service members overseas, the military maintains a robust anti-malarial drug development effort through internal research and commercial partnerships.
The NDA submission is a culmination of over 30 years of research and development with the U.S. Army Medical Research and Materiel Command, from the discovery of Tafenoquine at Walter Reed Army Institute of Research through the current collaboration between 60P and USAMMDA.
